Noninvasive Prenatal Testing Goes Global

Chandrasekharan, Subhashini; Minear, Mollie A.; Hung, Anthony; Allyse, Megan

doi:10.1126/scitranslmed.3008704

Cited by 126 publications

(103 citation statements)

References 7 publications

Supporting

Mentioning

100

Contrasting

Unclassified

Order By: Relevance

“…We recognize that while most research on the clinical implementation of NIPT has focused on North America and Western Europe, this technology must be responsive to local concerns as it spreads worldwide (Chandrasekharan et al 2014). In the final section of this special issue on NIPT, we have highlighted non-Western perspectives.…”

Section: Access and International Implementationmentioning

confidence: 99%

Old Questions, New Paradigms: Ethical, Legal, and Social Complications of Noninvasive Prenatal Testing

Michie

Allyse

2015

AJOB Empirical Bioethics

Self Cite

View full text Add to dashboard Cite

Section: Access and International Implementationmentioning

confidence: 99%

Old Questions, New Paradigms: Ethical, Legal, and Social Complications of Noninvasive Prenatal Testing

Michie

Allyse

2015

AJOB Empirical Bioethics

Self Cite

View full text Add to dashboard Cite

“…Whereas the abovementioned concerns were very prevalent in the "NIPD-days" -and are still tackled in the current literature on NIPT -other concerns now seem to garner more attention with the widespread introduction of NIPT, such as the equity of access that emerged as a frequent challenge for an appropriate clinical introduction of the test [5,7,80].…”

Section: Discussionmentioning

confidence: 99%

Non-Invasive Prenatal Testing: Review of Ethical, Legal and Social Implications

Haidar

Dupras

Ravitsky

2018

View full text Add to dashboard Cite

Droits d'auteur © H Haidar, C Dupras et V Ravitsky, 2016Ce document est protégé par la loi sur le droit d'auteur. L'utilisation des services d'Érudit (y compris la reproduction) est assujettie à sa politique d'utilisation que vous pouvez consulter en ligne.https://apropos.erudit.org/fr/usagers/politique-dutilisation/ Cet article est diffusé et préservé par Érudit.Érudit est un consortium interuniversitaire sans but lucratif composé de l'Université de Montréal, l'Université Laval et l'Université du Québec à Montréal. Il a pour mission la promotion et la valorisation de la recherche. Non-invasive prenatal testing (NIPT) using cell-free fetal DNA (cffDNA) from maternal blood has recently entered clinical practice in many countries, including Canada. This test can be performed early during pregnancy to detect Down syndrome and other conditions. While NIPT promises numerous benefits, it also has challenging ethical, legal and social implications (ELSI). This paper reviews concerns currently found in the literature on the ELSI of NIPT. We make four observations. First, NIPT seems to exacerbate some of the already existing concerns raised by other prenatal tests (amniocentesis and maternal serum screening) such as threats to women's reproductive autonomy and the potential for discrimination and stigmatization of disabled individuals and their families. This may be due to the likely upcoming large scale implementation and routinization of NIPT. Second, the distinction between NIPT as a screening test (as it is currently recommended) and as a diagnostic test (potentially in the future), has certain implications for the ELSI discussion. Third, we observed a progressive shift in the literature from initially including mostly conceptual analysis to an increasing number of empirical studies. This demonstrates the contribution of empirical bioethics approaches as the technology is being implemented into clinical use. Finally, we noted an increasing interest in equity and justice concerns regarding access to NIPT as it becomes more widely implemented. Mots clés Keywords Exonération DisclaimerLes évaluations des examinateurs externes sont prises en considération de façon sérieuse par les éditeurs et les auteurs dans la préparation des manuscrits pour publication. Toutefois, être nommé comme examinateur n'indique pas nécessairement l'approbation du manuscrit par cet examinateur. Les éditeurs de BioéthiqueOnline assument la responsabilité entière pour l'acceptation finale et la publication d'un article.Reviewer evaluations are given serious consideration by the editors and authors in the preparation of manuscripts for publication. Nonetheless, being named as a reviewer does not necessarily denote approval of a manuscript by the reviewer; the editors of BioéthiqueOnline take full responsibility for final acceptance and publication of an article.

show abstract

“…Following the launch of NIPT for autosomal aneuploidies, in late 2011, there has been an unprecedented uptake of testing in the private sector, largely driven by the commercial sector that wishes to capitalize on a potential market thought to be worth around $1.3 billion in the United States alone (Hayden 2012 (Chandrasekharan et al 2014). Initially, samples were sent to companies in China or the United States, but more recently there has been technology transfer and licensing of local organizations to increasingly allow NIPT to be offered regionally.…”

Section: Noninvasive Prenatal Diagnosis and Screeningmentioning

confidence: 99%

Noninvasive Prenatal Screening for Genetic Diseases Using Massively Parallel Sequencing of Maternal Plasma DNA

Chitty¹,

Lo²

2015

Cold Spring Harb Perspect Med

View full text Add to dashboard Cite

Noninvasive Prenatal Testing Goes Global

Abstract: Noninvasive prenatal genetic testing is becoming available worldwide—particularly in low- and middle-income countries—but practical and ethical challenges must be overcome.

Cited by 126 publications

References 7 publications

Old Questions, New Paradigms: Ethical, Legal, and Social Complications of Noninvasive Prenatal Testing

Old Questions, New Paradigms: Ethical, Legal, and Social Complications of Noninvasive Prenatal Testing

Non-Invasive Prenatal Testing: Review of Ethical, Legal and Social Implications

Noninvasive Prenatal Screening for Genetic Diseases Using Massively Parallel Sequencing of Maternal Plasma DNA

Contact Info

Product

Resources

About